ACT Genomics

ACT Genomics, established in 2014, provides optimal cancer treatment plans, cancer recurrence and drug resistance monitoring, as well as cancer risk assessment and immunotherapy evaluation through DNA sequencing-based technologies. The company achieves precise detection of cancer genetic variations with minimal tumor samples and offers personalized genomic-based treatment plans to each cancer patient via advanced NGS platforms, medical reports, and integrated services. It also utilizes artificial intelligence to deliver comprehensive data analysis on cancer genomics, integrating genomic database information with Asia-specific genomic profiles. ACT Genomics' comprehensive product portfolio has earned the company the 2017 Frost & Sullivan Asia-Pacific Molecular Diagnostics Product Line Strategy Leadership Award and Taiwan’s National Innovation Award.